Apnimed Inc. closed a highly successful US initial public offering, raising $192 million in an upsized deal that was priced at the top of a marketed range. The biotech company, focused on developing novel therapeutics for sleep apnea, capped its offering at $11.00 per share unapologetically setting a solid valuation marker.

Backed by pharmaceutical giant Shionogi, Apnimed has been aggressively advancing its lead candidate through late‑stage clinical trials, hoping to deliver a first‑in‑class treatment for obstructive sleep apnea. The partnership provides both financial and strategic support, reinforcing confidence among investors.

The IPO comprised 7.2 million shares with a $1.2‑billion equity valuation, positioning the company among the top performers in the biotech space this quarter. Pricing at the high end of the $10–$12 range underscored robust demand from institutional investors.

These fresh capital inflows will accelerate Apnimed's clinical roadmap, expand manufacturing capacity, and potentially fund additional acquisitions. The successful debut also signals growing appetite for niche therapeutic areas within the broader US biotech market.